Related papers: Three-Dimensional Amyloid-Beta PET Synthesis from …
Beta-amyloid positron emission tomography (A$\beta$-PET) imaging has become a critical tool in Alzheimer's disease (AD) research and diagnosis, providing insights into the pathological accumulation of amyloid plaques, one of the hallmarks…
In this work, an image translation model is implemented to produce synthetic amyloid-beta PET images from structural MRI that are quantitatively accurate. Image pairs of amyloid-beta PET and structural MRI were used to train the model. We…
Background: Alzheimer's disease (AD) diagnosis heavily relies on amyloid-beta positron emission tomography (Abeta-PET), which is limited by high cost and limited accessibility. This study explores whether Abeta-PET spatial patterns can be…
Recent studies suggest that combined analysis of Magnetic resonance imaging~(MRI) that measures brain atrophy and positron emission tomography~(PET) that quantifies hypo-metabolism provides improved accuracy in diagnosing Alzheimer's…
Detecting amyloid-$\beta$ (A$\beta$) positivity is crucial for early diagnosis of Alzheimer's disease but typically requires PET imaging, which is costly, invasive, and not widely accessible, limiting its use for population-level screening.…
Structural MRI-to-amyloid PET synthesis has been proposed as a non-invasive alternative for amyloid assessment in Alzheimer's disease (AD). However, reported performance of identical models varies widely across studies, and increasingly…
Positron Emission Tomography (PET) is an important tool for studying Alzheimer's disease (AD). PET scans can be used as diagnostics tools, and to provide molecular characterization of patients with cognitive disorders. However, multiple…
The integration of multimodal medical imaging can provide complementary and comprehensive information for the diagnosis of Alzheimer's disease (AD). However, in clinical practice, since positron emission tomography (PET) is often missing,…
Structural MRI and PET imaging play an important role in the diagnosis of Alzheimer's disease (AD), showing the morphological changes and glucose metabolism changes in the brain respectively. The manifestations in the brain image of some…
Identifying amyloid-beta positive patients is crucial for determining eligibility for Alzheimer's disease (AD) clinical trials and new disease-modifying treatments, but currently requires PET or CSF sampling. Previous MRI-based deep…
Alzheimer's disease (AD) is a major neurodegenerative condition that affects millions around the world. As one of the main biomarkers in the AD diagnosis procedure, brain amyloid positivity is typically identified by positron emission…
Structural magnetic resonance imaging (sMRI) combined with deep learning has achieved remarkable progress in the prediction and diagnosis of Alzheimer's disease (AD). Existing studies have used CNN and transformer to build a well-performing…
Accurate quantification of tau pathology via tau positron emission tomography (PET) scan is crucial for diagnosing and monitoring Alzheimer's disease (AD). However, the high cost and limited availability of tau PET restrict its widespread…
Imaging-based early diagnosis of Alzheimer Disease (AD) has become an effective approach, especially by using nuclear medicine imaging techniques such as Positron Emission Topography (PET). In various literature it has been found that PET…
Positron Emission Tomography (PET) is now regarded as the gold standard for the diagnosis of Alzheimer's Disease (AD). However, PET imaging can be prohibitive in terms of cost and planning, and is also among the imaging techniques with the…
Alzheimer's Disease (AD) is the most common form of dementia and often difficult to diagnose due to the multifactorial etiology of dementia. Recent works on neuroimaging-based computer-aided diagnosis with deep neural networks (DNNs) showed…
Positron emission tomography (PET) provides molecular biomarkers for Alzheimer's disease and related dementias (ADRD) and is increasingly used for diagnosis, staging, and clinical trial enrichment. However, its use is limited by cost,…
Synthesizing amyloid PET scans from the more widely available and accessible structural MRI modality offers a promising, cost-effective approach for large-scale Alzheimer's Disease (AD) screening. This is motivated by evidence that, while…
Alzheimer's disease (AD) is the most common cause of dementia. An early detection is crucial for slowing down the disease and mitigating risks related to the progression. While the combination of MRI and FDG-PET is the best image-based tool…
Alzheimer's disease is the most common neurodegenerative disorder. Its pathological development is connected with the misfolding and accumulation of two toxic proteins: amyloid-beta and tau proteins. Mathematical models provide a valuable…